155 related articles for article (PubMed ID: 32715799)
21. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation.
Sahasrabuddhe AA; Chen X; Chung F; Velusamy T; Lim MS; Elenitoba-Johnson KS
Oncogene; 2015 Jan; 34(4):445-54. PubMed ID: 24469040
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
23. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
24. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.
Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J
Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204
[TBL] [Abstract][Full Text] [Related]
25. Reaction coupling between wild-type and disease-associated mutant EZH2.
Swalm BM; Knutson SK; Warholic NM; Jin L; Kuntz KW; Keilhack H; Smith JJ; Pollock RM; Moyer MP; Scott MP; Copeland RA; Wigle TJ
ACS Chem Biol; 2014 Nov; 9(11):2459-64. PubMed ID: 25154026
[TBL] [Abstract][Full Text] [Related]
26. Stage-specific dual function: EZH2 regulates human erythropoiesis by eliciting histone and non-histone methylation.
Li M; Liu D; Xue F; Zhang H; Yang Q; Sun L; Qu X; Wu X; Zhao H; Liu J; Kang Q; Wang T; An X; Chen L
Haematologica; 2023 Sep; 108(9):2487-2502. PubMed ID: 37021526
[TBL] [Abstract][Full Text] [Related]
27. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
[TBL] [Abstract][Full Text] [Related]
29. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
30. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the histone methyltransferase EZH2 induces vascular stiffness.
Ibarrola J; Xiang RR; Sun Z; Lu Q; Hill MA; Jaffe IZ
Clin Sci (Lond); 2024 Mar; 138(5):251-268. PubMed ID: 38362910
[TBL] [Abstract][Full Text] [Related]
32. [EZH inhibitors in lymphoma therapy].
Ishitsuka K
Rinsho Ketsueki; 2023; 64(7):665-669. PubMed ID: 37544728
[TBL] [Abstract][Full Text] [Related]
33. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract][Full Text] [Related]
34. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
[TBL] [Abstract][Full Text] [Related]
35. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Bisserier M; Wajapeyee N
Blood; 2018 May; 131(19):2125-2137. PubMed ID: 29572378
[TBL] [Abstract][Full Text] [Related]
37. Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway.
Zhou T; Sun Y; Li M; Ding Y; Yin R; Li Z; Xie Q; Bao S; Cai W
Cell Death Dis; 2018 May; 9(6):590. PubMed ID: 29789597
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882
[TBL] [Abstract][Full Text] [Related]
39. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
[TBL] [Abstract][Full Text] [Related]
40. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
Al-Ghabkari A; Narendran A
Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
